相似文献
1
Evaluating the Utility of Combined Bladder Cancer Biomarkers, the Molecular Prognostication of Tumor Subtypes, or What Else Is Needed to Illuminate Our Vision?
Int J Mol Sci. 2020 Dec 18;21(24):9657. doi: 10.3390/ijms21249657.
2
Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
Expert Rev Mol Diagn. 2020 Feb;20(2):255-264. doi: 10.1080/14737159.2019.1680284. Epub 2019 Oct 17.
3
The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder.
Expert Rev Mol Diagn. 2020 Feb;20(2):127-129. doi: 10.1080/14737159.2019.1665509. Epub 2019 Sep 9.
4
Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision.
Int J Mol Sci. 2022 May 17;23(10):5620. doi: 10.3390/ijms23105620.
5
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
Expert Rev Mol Diagn. 2020 Feb;20(2):231-243. doi: 10.1080/14737159.2020.1699791. Epub 2019 Dec 11.
6
Bladder cancer: state-of-the-art care.
CA Cancer J Clin. 1998 Sep-Oct;48(5):269-84. doi: 10.3322/canjclin.48.5.269.
7
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S77-88. doi: 10.4111/icu.2016.57.S1.S77. Epub 2016 May 25.
8
Molecular Prognostication in Bladder Cancer.
Cancer Treat Res. 2018;175:165-191. doi: 10.1007/978-3-319-93339-9_8.
9
High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility.
Mol Oncol. 2008 Apr;1(4):384-94. doi: 10.1016/j.molonc.2007.11.002. Epub 2007 Dec 8.
10
Bladder cancer biomarkers: current developments and future implementation.
Curr Opin Urol. 2007 Sep;17(5):341-6. doi: 10.1097/MOU.0b013e3282c8c72b.
引用本文的文献
1
The potential link between the development of Alzheimer's disease and osteoporosis.
Biogerontology. 2025 Jan 20;26(1):43. doi: 10.1007/s10522-024-10181-z.
本文引用的文献
1
Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer.
Cancers (Basel). 2020 Nov 27;12(12):3541. doi: 10.3390/cancers12123541.
2
Activating Telomerase Promoter Mutations and Their Application for the Detection of Bladder Cancer.
Int J Mol Sci. 2020 Aug 21;21(17):6034. doi: 10.3390/ijms21176034.
3
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study.
Front Genet. 2019 Dec 18;10:1237. doi: 10.3389/fgene.2019.01237. eCollection 2019.
4
Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
EBioMedicine. 2019 Jun;44:431-438. doi: 10.1016/j.ebiom.2019.05.004. Epub 2019 May 20.
5
The Paris System for Reporting Urinary Cytology: the quest to develop a standardized terminology.
J Am Soc Cytopathol. 2016 May-Jun;5(3):177-188. doi: 10.1016/j.jasc.2016.04.005. Epub 2016 Apr 19.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
Diagnostic accuracy of the UBC Rapid Test for bladder cancer: A meta-analysis.
Oncol Lett. 2018 Sep;16(3):3770-3778. doi: 10.3892/ol.2018.9089. Epub 2018 Jul 5.
8
Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis.
Oncotarget. 2017 Oct 23;8(59):100648-100656. doi: 10.18632/oncotarget.22065. eCollection 2017 Nov 21.
9
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
10
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Urol Oncol. 2015 Feb;33(2):66.e25-31. doi: 10.1016/j.urolonc.2014.06.008. Epub 2014 Jul 15.
Zotero 插件